Larimar Therapeutics Inc. (LRMR)
2.64
-0.39 (-12.87%)
At close: Mar 03, 2025, 3:59 PM
2.65
0.38%
After-hours: Mar 03, 2025, 04:00 PM EST
Company Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease.
The company is based in Bala Cynwyd, Pennsylvania.
Larimar Therapeutics Inc.
| Country | United States |
| IPO Date | Jun 19, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Dr. Carole S. Ben-Maimon M.D. |
Contact Details
Address: Three Bala Plaza East Bala Cynwyd, Pennsylvania United States | |
| Website | https://www.larimartx.com |
Stock Details
| Ticker Symbol | LRMR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001374690 |
| CUSIP Number | 517125100 |
| ISIN Number | US5171251003 |
| Employer ID | 20-3857670 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carole S. Ben-Maimon M.D. | Chief Executive Officer, President & Director |
| Michael Celano CPA | Secretary & Chief Financial Officer |
| Dr. Gopi Shankar M.B.A., Ph.D. | Chief Development Officer |
| Dr. Russell G. Clayton Sr., D.O, D.O. | Chief Medical Officer |
| Francis Michael Conway CPA | Vice President & Controller |
| Jennifer Spokes Johansson | Vice President of Legal & Compliance |
| John Berman | Vice President of Finance & Administration |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 04, 2025 | SCHEDULE 13G | Filing |
| Jan 27, 2025 | 8-K | Current Report |
| Jan 24, 2025 | 4 | Filing |
| Jan 24, 2025 | 4 | Filing |
| Jan 24, 2025 | 4 | Filing |
| Jan 24, 2025 | 4 | Filing |
| Jan 10, 2025 | 8-K | Current Report |
| Jan 08, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Dec 16, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 8-K | Current Report |